Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2017

01-05-2017 | Original paper

Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis

Authors: Zhiyi Zhou, Fangfang Zeng, Jianhui Yuan, Jinling Tang, Graham A. Colditz, Shelley S. Tworoger, Britton Trabert, Xuefen Su

Published in: Cancer Causes & Control | Issue 5/2017

Login to get access

Abstract

Purpose

Previous studies on pelvic inflammatory disease (PID) and the risk of ovarian cancer have found inconsistent results. We performed an updated meta-analysis to summarize the evidence of this association.

Methods

PubMed, Embase, and ISI web of science databases were searched through October 2016 for studies that investigated the PID and ovarian cancer association. Summary risk estimates were calculated using random-effects meta-analysis.

Result

Thirteen studies were eligible for analysis, which included six cohort studies and seven case–control studies. PID was associated with an increased risk of ovarian cancer overall [relative risk (RR) 1.24, 95% CI 1.06–1.44; I 2  = 58.8%]. In analyses stratified by race, a significant positive association was observed in studies conducted among Asian women (RR 1.69, 95% CI 1.22–2.34; I 2  = 0%), but marginally significant among Caucasians (RR 1.18, 95% CI 1.00–1.39; I 2  = 60.7%).Risk estimates were elevated in both cohort (RR1.32; 95% CI 1.05–1.66; I 2  = 64.7%) and case-control studies (RR 1.17; 95% CI 0.93–1.49; I 2  = 57.6%), albeit not statistically significant in case–control studies.

Conclusions

Our results suggested that PID might be a potential risk factor of ovarian cancer, with pronounced associations among Asian women. Large and well-designed studies with objective assessment methods, such as hospital records, are needed to confirm the findings of this meta-analysis.
Literature
1.
2.
3.
Schwartz PE (2003) Diagnosis and treatment of epithelial ovarian cancer. Minerva Ginecol 55:315–326PubMed
4.
Trope CG, Kaern J, Davidson B (2012) Borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 26(3):325–336CrossRefPubMed
5.
6.
Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467CrossRefPubMed
7.
Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4:447–451PubMed
8.
Kisielewski R, Tołwińska A, Mazurek A, Laudański P (2013) Inflammation and ovarian cancer–current views. Ginekol Pol 84:293–297CrossRefPubMed
9.
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N; Ovarian Cancer Association Consortium (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. J Natl Cancer Inst 106:djt431CrossRefPubMedPubMedCentral
10.
11.
Kurman RJ, Shih IeM (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42:918–931CrossRefPubMedPubMedCentral
12.
Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC (2011) Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res 4:463–470CrossRef
13.
Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMed
14.
Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, Wu SC, Lai YL (2011) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904CrossRefPubMed
15.
McAlpine JN, Lisonkova S, Joseph KS, McComb PF (2014) Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study. Int J Gynecol Cancer 24:1406–1413CrossRefPubMed
16.
Lareau SM, Beigi RH (2008) Pelvic inflammatory disease and tubo-ovarian abscess. Infect Dis Clin N Am 22:693–708CrossRef
17.
Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group (2008) Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122:170–176CrossRefPubMed
18.
Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC (2009) Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 124:1409–1415CrossRefPubMedPubMedCentral
19.
Stewart LM, Holman CD, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R (2013) In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 128:260–264CrossRefPubMed
20.
Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK (2017) Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiol Biomarkers Prev 26:104–109CrossRefPubMed
21.
Rasmussen CB, Faber MT, Jensen A, Hogdall E, Hogdall C, Blaakaer J, Kjaer SK (2013) Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors. Cancer Causes Control 24:1459–1464CrossRefPubMed
22.
Shen CC, Hu LY, Yang AC, Chiang YY, Hung JH, Tsai SJ (2016) Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study. BMC Cancer 16:839CrossRefPubMedPubMedCentral
23.
Rasmussen CB, Jsensen A, Albieri V, Andersen KK, Kjaer SK (2016) Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study. Gynecol Oncol 143:346–351CrossRefPubMed
24.
Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case–control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMed
25.
Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ (2000) Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11:111–117CrossRefPubMed
26.
27.
28.
29.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
30.
31.
Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54:1046–1055CrossRefPubMed
32.
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed
33.
Rasmussen CB, Kjaer SK, Albieri V, Bandera EV, Doherty JA, Høgdall E, Webb PM, Jordan SJ, Rossing MA, Wicklund KG, Goodman MT, Modugno F, Moysich KB, Ness RB, Edwards RP, Schildkraut JM, Berchuck A, Olson SH, Kiemeney LA, Massuger LF, Narod SA, Phelan CM, Anton-Culver H, Ziogas A, Wu AH, Pearce CL, Risch HA, Jensen A; on behalf of the Ovarian Cancer Association Consortium. (2016) Pelvic inflammatory disease and the risk of ovarian cancer and borderline ovarian tumors: a pooled analysis of 13 case–control studies. Am J Epidemiol 185:8–20.CrossRefPubMed
34.
Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373–2380CrossRefPubMed
35.
36.
Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. II. Invasive epithelial ovarian cancers in white women.. Am J Epidemiol 136:1184–1203CrossRefPubMed
37.
Wang LY, OuYang L, Tong F, Zhang XJ, Li XD, Wang CC, Li X, Sun L, Sun YH (2016) The effect of contraceptive methods on reproductive tract infections risk: a cross-sectional study having a sample of 52,481 women. Arch Gynecol Obstet 294:1249–1256CrossRefPubMed
38.
Riman T, Nilsson S, Persson IR (2004) Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83:783–795CrossRefPubMed
39.
He J, Gao X, Ren Z (2009) Global Incidence patterns of female breast and ovarian cancers. China Cancer 18:169–172
40.
Beavis AL, Smith AJ, Fader AN (2016) Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management. Int J Womens Health 8:151–167PubMedPubMedCentral
41.
Marshall M, Solomon S (2007) Hereditary breast-ovarian cancer: clinical findings and medical management. Plast Surg Nurs 27:124–127CrossRefPubMed
Metadata
Title
Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis
Authors
Zhiyi Zhou
Fangfang Zeng
Jianhui Yuan
Jinling Tang
Graham A. Colditz
Shelley S. Tworoger
Britton Trabert
Xuefen Su
Publication date
01-05-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 5/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0873-3

Other articles of this Issue 5/2017

Cancer Causes & Control 5/2017 Go to the issue

Original paper

Trends in hormone use and ovarian cancer incidence in US white and Australian women: implications for the future

Original paper

Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women

Original paper

Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles

Original paper

Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium

Original paper

Ovarian cancer epidemiology in the era of collaborative team science

Original paper

Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits